Search Results
Nov 18, 2025, 08:05 ET Creatine Hydrochloride Found to Mitigate Physical and Cognitive Symptoms in Groundbreaking Study on Menopause
Improvements: Low-dose CrHCL (750 mg/day) significantly improved alertness, executive control, processing speed, and reaction times. Medium-dose CrHCL (1,500 mg/day) enhanced reaction times and reduced mood swings and concentration difficulties. CrHCL-CEE (800 mg/day) alleviated anxiety and improved alertness.
More news about: CON-CRĒT
Nov 18, 2025, 08:00 ET Mabloc and Instituto Butantan Partner to Advance First-in-Class Antibody Therapy for Yellow Fever
bioinformatics to rapidly identify, optimize, and test potent antibodies. In a primate study published in Science Translational Medicine (2023), a single 50mg/kg dose of MBL-YFV-01 fully controlled viremia and prevented severe disease and death in 100% of treated primates. This was followed up with additional
More news about: Mabloc
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
In the Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI.
More news about: Acurx Pharmaceuticals, Inc.
Nov 18, 2025, 07:32 ET Medunik USA reaffirms support for Sickle Cell Disease community with uninterrupted supply and Patient-Centered Services
Siklos® is also the only hydroxyurea formulation available in scored 100 mg and triple-scored 1,000 mg dissolvable tablets, making it ideally suited for body-weight dosing adjustments in 50 mg increments. From childhood to adulthood, Siklos® adapts – tablets can be either dissolved
More news about: Medunik USA
Nov 18, 2025, 07:19 ET Monteloeder Botanical Nutricosmetic Clinically Supports Younger Looking Skin
ages of 33 and 66 showing visible signs of skin aging. Conducted at the Centro Médico Complutense in Spain, the participants were assigned either a 225mg capsule of Eternalyoung® or a placebo taken daily over a period of 12 weeks. The results revealed that
More news about: Monteloeder, S.L.
Nov 17, 2025, 18:37 ET Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
GLP-1 agonist experience. Participants were injected with 1 mg Wegovy®, a dose that normally takes 9 weeks of titration to reach under current prescribing guidelines. Participants were pretreated with tradipitant 85 mg twice daily or placebo for 1 week, followed by 1 week of continued
More news about: Vanda Pharmaceuticals Inc.
Nov 17, 2025, 18:00 ET 유럽 가금류 업계, 동물에 대한 예방적이고 책임 있는 접근 강조
사용이 금지됐다. 항생제는 치료 목적일 때만, 그리고 엄격한 수의학적 감독하에서 사용이 허용된다. 또한 농약 허용물질목록 관리제도(Positive List System, PLS) 규정이 적용되며, 잔류 허용 기준(MRL)이 설정되지 않은 경우 0.01ppm(0.01 mg/kg)의 매우 엄격한 기본 기준치가 적용된다. 이 같은 명확한 규정은 식품 안전과 공급망 투명성을 강화하기 위해 마련된 것이다. 유럽의 생산 방식은 수의사 감독 원칙, 전 과정 추적성, 위험 평가를 기반으로 하며, 이는 한국 산업
More news about: Poland’s National Poultry Council - Chamber of Commerce (KRD-IG)
Nov 17, 2025, 17:31 ET Sepsis Market is Projected to Boost at a CAGR of 5.1% in the US During the Forecast Period (2025-2034) | DelveInsight
treatments, such as corticosteroids, are recommended for cases of septic shock unresponsive to fluids and vasopressors, with hydrocortisone (200 mg/day) as the standard therapy. Steroids improve vascular tone and circulating volume through both glucocorticoid and mineralocorticoid effects. Emerging
More news about: DelveInsight Business Research, LLP
Nov 17, 2025, 16:31 ET Estudo da Novo Nordisk descreve associações entre o uso de Wegovy® e gastos com álcool e tabaco
Análise de dados de mundo real com mais de 200 mil lares americanos mostrou que famílias com usuários de Wegovy® (semaglutida 2,4 mg) registraram uma queda nos gastos com álcool e tabaco em comparação com não usuários¹. Além de seu efeito já bem estabelecido
More news about: Novo Nordisk
Nov 17, 2025, 11:53 ET ONE HEMP Urges Immediate Action on Misguided Federal Hemp Restrictions
open up the government – in the Agriculture, Rural Development, and FDA Appropriations Act - bans full-spectrum CBD products through an arbitrary 0.4 mg total THC per container limit. This unscientific threshold would strip millions of Americans of access to safe, non-intoxicating CBD products they rely
More news about: ONE HEMP
Nov 17, 2025, 11:49 ET ANS abre consulta pública para decidir sobre a inclusão de novo medicamento para dermatite atópica
avermelhadas ou escuras, coceira e ressecamento. [18] [19] [20] [21] A injeção de 250 mg/2 mL pode ser usada com ou sem corticosteroides tópicos e é administrada como uma única injeção de manutenção mensal, de 250 mg a cada quatro semanas após o período de indução do tratamento. [19]
More news about: Eli Lilly do Brasil
Nov 17, 2025, 09:27 ET 復宏漢霖與Organon共同宣佈美國首個帕妥珠單抗生物類似藥POHERDY®獲FDA批准
上海和新澤西州澤西市 2025年11月17日 /美通社/ -- 復宏漢霖（2696.HK）與Organon（紐交所代碼：OGN）今日共同宣佈，帕妥珠單抗注射液（420 mg/14 mL）POHERDY®（pertuzumab-dpzb）生物製品許可申請（BLA）獲美國食品藥品監督管理局（FDA）批准，並可與原研產品PERJETA（pertuzumab）互換使用，成為美國首款且唯一的PERJETA生物類似藥，覆蓋其在美國已獲批的所有適應症
More news about: 復宏漢霖
Nov 17, 2025, 08:05 ET New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
. Dosage Forms and Strengths: TREMFYA® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion. ABOUT JOHNSON & JOHNSONAt
More news about: Johnson & Johnson
Nov 17, 2025, 08:05 ET Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
If differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms. If concomitant leukocytosis is observed, initiate treatment with
More news about: Rigel Pharmaceuticals, Inc.
Nov 17, 2025, 07:45 ET Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month
injection 0.25 mg and 0.5 mg and Ozempic® are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026. This introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy®
More news about: Novo Nordisk
Nov 17, 2025, 06:30 ET Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Phase 1/2 clinical trial for patients with advanced ALK-positive NSCLC and other solid tumors. The recommended Phase 2 dose (RP2D) for neladalkib of 150 mg once daily (QD) was determined during the Phase 1 dose-escalation portion of the trial. The global, single-arm, multi-cohort, open-label Phase 2 portion
More news about: Nuvalent, Inc.
Nov 14, 2025, 10:01 ET ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma
More news about: Faruqi & Faruqi, LLP
Nov 14, 2025, 09:38 ET JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Faruqi & Faruqi, LLP
Nov 14, 2025, 07:00 ET Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
(REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials, with 180-day CGT exclusivity in the U.S. This follows the recent approval received from the United States
More news about: Lupin Limited
Nov 14, 2025, 05:08 ET EirGenix unterzeichnete die kommerzielle Lizenzvereinbarung für sein zweites HER2-Biosimilar EG1206A
EirGenix weiter. Die beiden Unternehmen hatten zuvor einen globalen Vermarktungsvertrag für EG12014 (Trastuzumab-Biosimilar in den Formulierungen 150 mg und 420 mg) unterzeichnet. EG12014 wurde bereits von der Europäischen Kommission zugelassen und befindet sich derzeit im BLA-Verfahren bei der amerikanischen
More news about: EirGenix, Inc.
Nov 14, 2025, 03:36 ET Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
days per month and headache occurring on >14 days. Participants were randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo. The double-blind, placebo-controlled treatment period was followed by an extension period where all participants
More news about: H. Lundbeck A/S
Nov 13, 2025, 18:51 ET Leqembi® approved for IV maintenance treatment in the United Kingdom
approval for IV maintenance dosing, after 18 months of a dosing regimen of 10 mg/kg once every two weeks, patients may be transitioned to a maintenance dosing regimen of 10 mg/kg once every four weeks, or they may continue with 10 mg/kg once every two weeks . In the United Kingdom, an
More news about: BioArctic
Nov 13, 2025, 18:50 ET Leqembi® approved for IV maintenance treatment in the United Kingdom
approval for IV maintenance dosing, after 18 months of a dosing regimen of 10 mg/kg once every two weeks, patients may be transitioned to a maintenance dosing regimen of 10 mg/kg once every four weeks, or they may continue with 10 mg/kg once every two weeks . In the United Kingdom, an
More news about: BioArctic
Nov 13, 2025, 17:31 ET ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
therapeutic advancement. The OASIS 4 trial, published simultaneously in The New England Journal of Medicine, demonstrated that oral semaglutide at 25 mg once daily resulted in a mean body weight reduction of 14%, compared to 2% with placebo. Notably, 30% of participants achieved a≥20% weight loss, compared
More news about: DelveInsight Business Research, LLP
Nov 13, 2025, 16:05 ET Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
MESI subjects at the 5 mg and 10 mg dose levels versus sham. About PEAK and PINNACLE The PEAK and PINNACLE studies are superiority studies evaluating two dose levels of KSI-101 (5 mg and 10 mg) compared to sham treatment
More news about: Kodiak Sciences Inc.